Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03010358
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:38.140387+00:00
Published At
2023-08-08T00:00:00+00:00
Record Updated At
2023-08-08
Results Posted At
2023-08-08
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Anemia", "B-Cell Prolymphocytic Leukemia", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma", "Hairy Cell Leukemia", "Lymphoplasmacytic Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Small Lymphocytic Lymphoma", "Richter Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-08-08"
protocolSection.identificationModule.nctId
"NCT03010358"
protocolSection.identificationModule.officialTitle
"A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-08-08"

Study condition terms

  • Anemia (protocolSection.conditionsModule.conditions)
  • B-Cell Prolymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Grade 1 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Grade 2 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Grade 3a Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Hairy Cell Leukemia (protocolSection.conditionsModule.conditions)
  • Lymphoplasmacytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Richter Syndrome (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.